Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion

Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma?

(2011) Raghava Reddy et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline

(2011) Pamela U. Freda et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Inhibitory Effects of Antivascular Endothelial Growth Factor Strategies in Experimental Dopamine-Resistant Prolactinomas

(2011) G. M. Luque et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Non-functioning pituitary adenomas

(2009) Yona Greenman et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

The dopamine–somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways

(2009) Erika Peverelli et al.   CANCER LETTERS

Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1

(2008) N. Korsisaari et al.   CLINICAL CANCER RESEARCH

Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study

(2008) T. Florio et al.   ENDOCRINE-RELATED CANCER

Medical therapy for clinically non-functioning pituitary adenomas

(2008) A. Colao et al.   ENDOCRINE-RELATED CANCER